In:
International Journal of Cancer, Wiley, Vol. 135, No. 7 ( 2014-10), p. 1596-1604
Abstract:
What's new? For an asymptomatic tumor like prostate cancer, saving lives depends on early diagnosis. But PSA testing identifies many cancers that might never become harmful, leading to expensive, unnecessary treatments. Thus, the search is on for a test to identify only those cancers likely to cause harm. This study examined serum levels of a cancer marker, IMP3, and found that patients with prostate cancer had higher levels of circulating IMP3 than those with benign prostate hyperplasia. Higher levels correlated with poorer survival, and those whose cancers metastasized had the highest amounts, suggesting this marker might help identify the most dangerous cancers.
Type of Medium:
Online Resource
ISSN:
0020-7136
,
1097-0215
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
218257-9
detail.hit.zdb_id:
1474822-8
Permalink